HSP90 inhibitors, on the other hand, disrupt the function of HSP90 family, chaperones involved in properly folding and stabilizing client proteins, including many involved in cancer progression (Kudlova et al. 2022). This evidence concerns the gene HSP90AB1 and cancer.